Author

Spencer-Segal Joanna L.

OpenAlex ID: A5113201848

An open-label long-term Phase 3 study of CAM2029 in patients with acromegaly (ACROINNOVA 2): interim analysis of the subgroup of patients 'new to CAM2029' with controlled or uncontrolled acromegaly on standard-of-care treatment

2024 · Diego Ferone, Spencer-Segal Joanna L., et al. · Endocrine Abstracts · 1

An open-label long-term Phase 3 study of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly (ACROINNOVA 2): interim analysis of the ACROINNOVA 1 roll-over patients subgroup

2024 · Diego Ferone, Julie Silverstein, et al. · Endocrine Abstracts · 1

CAm2029 octreotide subcutaneous depot provides stable control of IGF-I and improves key symptoms throughout a 4-week post-dose interval: analysis from the ACROINNOVA 1 trial

2025 · Gadelha Monica R., Biller Beverly M.K., et al. · Endocrine Abstracts

CAM2029, a self-administered subcutaneous octreotide depot, improved pros and symptoms in patients with ACROMEGALY in the acroinnova 2 phase 3 trial: final analysis of the core phase results

2025 · Diego Ferone, Biller Beverly M.K., et al. · Endocrine Abstracts

A randomised phase 3 trial to assess efficacy and safety of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly

2024 · Diego Ferone, Julie Silverstein, et al. · Endocrine Abstracts

An open-label long-term Phase 3 study of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly (ACROINNOVA 2): interim analysis of patient-reported outcomes

2024 · Diego Ferone, Pietro Maffei, et al. · Endocrine Abstracts

Works count: 6

Citation count: 2

H-index: 1

I10-index: